Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Signs on Lawrence Livermore Lab as eTag Customer

NEW YORK, April 8 - Lawrence Livemore National Laboratory will use Aclara's eTag assay system for a biological agent detection program, Aclara said today.

 

Under the agreement, Aclara, of Mountain View, Calif.,  will provide LLNL scientists with eTag assay reagents, software, and services. LLNL scientists will develop miniaturized assays for detection of  biological agents.

 

LLNL chose the eTag assays because of high sensitivity, high specificity and the ability to detect a "broad spectrum" of biological pathogens, Steven Visuri, a Senior Scientist in LLNL's Chemical and Biological National Security Program, said in a statement.

 

The eTag system uses Aclara's eTag reporters for multiplex gene or protein analysis in a single sample.

 

This announcement follows closely on Aclara's recent management changes.

 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.